GLP-1 treatment and hair shedding
Hair loss is reported in the Zepbound trials, and its label associates those reactions with weight reduction. Separately, the American Academy of Dermatology lists substantial weight loss as a trigger for delayed hair shedding. Neither observation identifies the cause in every person or proves that a hair supplement will help.
Hair-loss reports in Zepbound Studies 1 and 2
Swipe or scroll sideways to compare all columns.
| Group | Zepbound | Placebo |
|---|---|---|
| Female participants | 7.1% | 1.3% |
| Male participants | 0.5% | 0% |
What these percentages mean
These are adverse-reaction reports in two pooled Zepbound studies, not a rate for all GLP-1 medicines or a prediction for an individual. The label associates the reports with weight reduction. It does not say that every case had the same cause.
A trigger is not a diagnosis
AAD describes excessive shedding that can appear a few months after a stressor such as substantial weight loss. Note when weight, food intake and shedding changed. That timeline helps describe the problem; it does not distinguish every cause or establish that the most recent medicine must be responsible.
Where the nutrition evidence fits
The GLP-1 nutrition advisory discusses individually tailored correction of nutrient risks. It does not identify one universal hair-growth stack. A dietary review answers a different question from whether a specific hair product has demonstrated a treatment effect.
Use the table and its sources
Related reading
CompareOrforglipron vs oral semaglutide
Orforglipron lowered HbA1c more than oral semaglutide in ACHIEVE-3, but gastrointestinal events were more frequent.
CompareRetatrutide vs tirzepatide
Tirzepatide targets GIP and GLP-1 receptors; retatrutide also targets the glucagon receptor.
ReadGLP-1 weight loss and muscle
Weight lost during GLP-1 treatment is not all fat.
ReadCreatine with GLP-1: the trial
Creatine during GLP-1 treatment is being tested directly.
ReadVitamins during GLP-1 treatment
There is no single vitamin stack in the joint nutrition advisory for everyone taking a GLP-1 medicine.
Source-linked editorial synthesis, prepared with AI assistance. This is not a clinician review or a personalised treatment recommendation. Corrections: editorial standards.